Brief ReportBrief Communication
Open Access

Spectrum of medulloblastoma subtypes and frequency of MYC amplification; Experience from a tertiary care center in Saudi Arabia

Ali H. Alassiri, Fahd M. Alsufiani, Ahmed A. Almutairi, Ibrahim A. Almohini, Mohammed A. Aldosari and Mohammed F. Essa
Neurosciences Journal July 2020, 25 (3) 218-221; DOI: https://doi.org/10.17712/nsj.2020.3.20190124

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    Kaplan Meier survival curves. a) The 2 MYC amplified (green), one MYCN amplified (blue), and the remaining 15 non-amplified cases (yellow); b) The two MYC amplified cases (blue) versus the remaining 17 non-amplified cases (green). c) The one MYCN amplified case (blue) versus the remaining 18 non-amplified cases (green).

Tables

  • Table 1

    Demographics and clinicopathological data. N=57

    DemographicsTotaln (%)
    Sex
    Male27 (47.4)
    Female30 (52.6)
    Age
    ≤14 years29 (50.9)
    >14 years28 (49.1)
    Histology Subtypes
    Classic39 (68.4)
    Desmoplastic/nodular12 (21.1)
    Anaplastic/large-cell4 (7.2)
    With extensive nodularity2 (3.5)
    Molecular Subtypes
    Non-WNT/non-SHH12 (63.2)
    SHH-activated6 (31.6)
    WNT-activated1 (5.3)
    MYC Status
    Amplified2 (10.5)
    Not-amplified17 (89.5)
    MYCN Status
    Amplified1 (5.3)
    Not-amplified18 (94.7)
  • Table 2

    MYC and MYCN amplification statuses and outcomes parameters in relation to the histologic subtypes.

    Histological subtypesTotal
    ClassicWith extensive nodularityAnaplastic/large-cellDesmoplastic/nodularn (%)
    MYC amplification
    Positive0ND**202 (10.5)
    Negative9ND**2617 (89.5)
    MYCN amplification
    Positive1ND**001 (5.3)
    Negative8ND**4618 (94.7)
    *Metastasis50117 (17.9)
    *Recurrence42208 (14)
    *Mortality20215 (8.8)

    • ↵* Follow up period is 5 years from the date of diagnosis

    • ↵** ND - Not done

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section